Zheng Quan Zhi Xing·2025-05-22 12:47Core Viewpoint - The company, Tonghua Dongbao Pharmaceutical Co., Ltd., plans to transfer 23,187,600 shares of Xiamen Te Bao Biological Engineering Co., Ltd. at a price of 56.12 yuan per share, totaling approximately 1.301 billion yuan, to focus on its transformation into an innovative pharmaceutical company [1][3][5]. Transaction Overview - Before the transfer, the company held 65,200,114 shares of Te Bao Biological, representing 16.03% of its total share capital [1][2]. - The board of directors approved the transfer on May 22, 2025, and the transaction is subject to shareholder approval [2][3]. - The transaction does not constitute a related party transaction or a major asset restructuring [1][3]. Purpose and Impact of the Transaction - The share transfer is part of the company's strategy to accelerate its transformation into an innovative pharmaceutical enterprise, aiming to enhance capital efficiency and support the development of innovative drugs [3][5]. - The transaction is expected to have a significant impact on the company's current profits, with the actual profit contribution to be determined by audit results [5]. Counterparty Information - The counterparty for the share transfer is Tibet Trust Co., Ltd., representing the "Tibet Trust - Jintong No. 35 Collective Fund Trust Plan" [6]. - There are no existing relationships between the company and the counterparty that could affect the transaction [6]. Share Transfer Agreement Details - The total transfer price is set at 1,301,288,112 yuan, with specific payment terms outlined in the agreement [6][7]. - The agreement includes provisions for confidentiality, dispute resolution, and conditions for the agreement's effectiveness [8][9].